Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Considering he is a known liar about NWBO data whom Liau had to correct. He used to always pass off pseudoprogressors as rapid progressors in the information arm presentations he gave and then when Liau gave them she said they were pseudoprogressors. Gee, giving DCVax to a bunch of pseudoprogressors and calling them rapid progressors makes DCVax look like it actually does something.
I think they’re trying to ride the coattails of what DCVax has proven. It seems the medical community is trying to use MRNA technology for everything they can imagine since it was just dumped on the world population during covid, as if that’s validation to use it for other diseases and cancer treatments.
I don’t think MRNA technology is promising and from what I’ve read has a horrible safety profile. It’s fine that you posted it, though.
Yeah, right. That's exactly Dr Liau had in mind when she said
Interesting grammatical tense selection.
Inquirig said:
And it seems U of F, Moderna and IBRX are leading the way.
Cool
Nothing yet from the silent corrupt scam company, as usual.. One of their anonymous surrogates will opine soon.
Doesn't change the fact that it will most likely be granted. The flim flam is just about over.
All posts are my opinions
Is it next Friday yet?
For what it’s worth, while I still believe an MAA decision could come any day, studying the NICE STA timeline again, scribbling down external comments and events, and looking at the 150 day MHRA process (room for flexibility) over and over, I think FeMike might be closest with an end of June aspiration. While I don’t agree with him that's the best one could hope for, I do believe that’s somewhat more likely than anything earlier or later.
I do believe some potential intervening preceding events, publications or deals for instance, still have a chance to catch many off guard.
Did I break any laws? No, I didn't think so.
Apparently you are a very bad investor... Your AVXL is at a 4 year low, and your NWBO investment is down over 99% in the last decade.
Focus on yourself, little man.
Any interpretation on the MTD filing yet?
Changing the assumed validation date as well (Dec 20 + 14).
DCVAX-L MAA TRACKER
134 days from December 20th SUBMISSION
120 days from January 3rd VALIDATION (assumed)
Days to Decision from VALIDATION
30 days - 150 day with no RFI - June 1st
90 days - 210 day with RFI - July 31st
150 days - 270 day with RFI - September 29th
Thanks Flip, I'll edit it for tomorrow
Speaking of things that don't work....
Your id was created 12/26/23. That was 128 days ago. You have made 2190 posts in those 128 days. That works out to slightly over 17 posts a day.
Posts worth reading in that 128 days, zero.
"Who let him out?"
Better yet, who let you in???
Another one with no sense of humor. Who let him out?
Resistance may be futile but bullshit is inevitable.
This never gets old. So I list the patent here again.
https://patents.google.com/patent/US20150202291A1/en
Current Assignee: RevImmune Inc; University of California; Northwest Biotherapeutics LLC; Cognate Bioservices Inc
NCI did the trial using DCVax-L combined with CYT107. I would not be surprised that RevImmune as a solely private-owned company and the owner of the patent uses this above combination to do some clinical trials on other targets.
Stonkmaster, I noticed your countdown repeated itself around April 29th and 30th.
We are actually 134 days from submission, and everything else is a day different as well.
No criticism, just letting you know.
I waited till the price came up to $0.17 & $0.18....😎
What about Liau, Brem, Iwamoto, Pluward, Prins, and Pearlman????? LOL
This whole thing is a laughing fest. The trial failed and they tried using band aids 4 years later... That is why it's an OTCBB stock scam, seeking tiny approval in the neither-lands of the UK, and it's doubtful there also... .... IMHO
You don't have to cover when it hits zero
Nothing against Bosch but I'm genuinely surprised JAMA would allow it.
>>Author Contributions: Dr Bosch had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
when r these short bad aces goin to cover? After the good news?? Looks like LP got an ant pit of good news coming out in a series; starting any minute.
Why would they purchase more? They already hold millions of shares and are assured of the future potential. Daily price fluctuations don't bother them, but what worries me is the continuous dilution of the stock. The only saving grace for the stock price is MHRA approval. This stock remains largely unaffected by fluctuations in the stock market. Sometimes, I feel like dreaming of this stock reaching over $10 is akin to grasping at a mirage. Hopefully, this month and the next will bring much-needed relief to us, including the GBM patients suffering from a lack of financial assistance.
EXPERTS?????
First of all, JAMA does not approve drugs. LOL
Secondly, that is over 2 years old
Thirdly: The conflicts here are enormous!
*******Drs Boynton and Bosch reported being employees of and owning shares in Northwest Biotherapeutics, Inc. Dr Boynton reported having a patent held by Northwest Biotherapeutics. Dr Bosch reporting having patent 13/492693 pending.Conflict of Interest *****
Disclosures: Dr Liau reported serving on the board of directors of ClearPoint Neuro outside the submitted work and having a patent pending for combinations of inhibitors with dendric cell vaccines to treat cancer. Dr Ashkan reported receiving grants from Northwest Biotherapeutics during the conduct of the study. Dr Brem reported receiving travel support from Northwest Biotherapeutics outside the submitted work. Dr Campian reported receiving grants from NeoImmue Tech and support for investigator-initiated clinical trials from Incyte, Merck, and Ipsen outside the submitted work. Dr Iwamoto reported receiving grants from Northwest Biotherapeutics and serving on the steering committee of this trial during the conduct of the study and receiving personal fees from AbbVie, Alexion, Gennao Bio, Novocure, Kiyatec, Medtronic, Merck, Guidepoint, Mimivax, Massive Bio, Tocagen, Regeneron, and Xcures outside the submitted work. Dr Tran reported receiving grants from Novocure, Moteris, Lacerta, Sarepta, Merck, Novartis, Northwest Biotherapeutics, Stemline, Celldex, Orbus, TVax, and Tocagen; receiving travel support from Novartis; and serving on the advisory board of Novocure during the conduct of the study. Dr Goldlust reported receiving institutional support from Northwest Biotherapeutics during the conduct of the study; receiving consulting fees from Boston Biomedical, Sumitomo Danippon Pharma, Cornerstone Specialty Network, Cellevolve, Daiichi Sankyo, and Novocure; serving on the speakers’ bureau for Novocure and Physicians Education Resources; receiving food and drink from Novocure; and owning stock in COTA outside the submitted work. Dr Grewal reported receiving personal fees from AstraZeneca, Vivacitas Oncology, and xCures; receiving sample medication from AbbVie/Allergan; and being the founder of Genomet outside the submitted work. Dr Avigan reported serving on the advisory boards of Bristol Myer Squibb, Chugai, Merck, Kite, and Legend; receiving grants from Sanofi, and serving as a consultant for Parexel outside the submitted work. Dr Fink reported receiving funding from Northwest Biotherapeutics during the conduct of the study and receiving funding from Novocure, Denovo Biopharma, Stemline, CNS Pharmaceuticals, Servier Pharmaceuticals/Agios, and Sumitoma Pharma outside the submitted work. Dr Giglio reported receiving study support from the Medical University of South Carolina during the conduct of the study; receiving grants from Denovo Biopharma, Novocure, BioMimetix, Celgene, EORTC, the Canadian Cancer Trials Group, Institut de Recherches Internationales Servier, the Global Coalition for Adapative Research, and Prelude outside the submitted work; and having a patent pending for the epitranscriptomic analysis of glioma. Dr Lutzky reported receiving grants from Bristol Myer Squibb and serving on the advisory boards of Iovance and Castle outside the submitted work. Dr Meisel reported receiving personal fees from BG Klinikum Bergmannstrost during the conduct of the study and receiving consulting fees paid to Regenerate Life Sciences from Stayble Therapeutics and royalties from Fehling Instruments outside the submitted work. Dr Sanchin reported receiving personal fees from BG Klinikum Bergmannstrost during the conduct of the study. Dr Dunbar reported receiving speaking fees from GT Medical during the conduct of the study. Dr Pluward reported receiving grants from Northwest Biotherapeutics during the conduct of the study. Dr Mulholland reported receiving support to attend a conference from Northwest Biotherapeutics during the conduct of the study. Dr Pearlman reported receiving compensation for serving as a site principal investigator from Northwest Biotherapeutics during the conduct of the study. Dr Prins reported having patent UCLA Case No. 2015-341 pending. Drs Boynton and Bosch reported being employees of and owning shares in Northwest Biotherapeutics, Inc. Dr Boynton reported having a patent held by Northwest Biotherapeutics. Dr Bosch reporting having patent 13/492693 pending.
The experts strong disagree with you (an anonymous message board poster):
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
DCVax is like an 8 track cassette tape,... that doesn't work.
RNA is all the rage
https://www.sciencedaily.com/releases/2024/05/240501125736.htm
Apparently bringing information to this board is not without controversy.
I would have thought that the similarities i.e. using tumor tissues would be considered a bit of validation for NWBO approach.
Volume hasn't been this low since the end of June 2023.
Eye of the storm!!
If mgt would have started buying stock at 100000 month last year , the stock would have gone up everyday with that obvious confidence
Not the share price because for years they've been flooding the market with shares on your pumping. You keep the sp above the conversion / strike price with a few runs here and there. Your pumps only serve to inflate market cap. Then the rug pull comes.
8 bucks is way too low. I think the company is worth a lot more as a holding/franchising outfit.
I think LP said she want to go to NYSE.
believe that is the CHM meeting, may or may not have already happened.
Doesn't MRHA have anything like ADCOM?
We are the Disciples. Lower your IQ and surrender your cash. We will add your gullible genetic distinctiveness to our own. Incurious retail will adapt to service us. Resistance is futile.
"Thanks for contacting GOV.UK.
Your query has been passed to the Medicines and Healthcare Products Regulatory Agency, who manage this material. They will investigate and respond to you directly. Unfortunately, we can't give an estimated time when the department will reply.
In the meantime your original query with GOV.UK will be closed.". CLOSED? LOL And some here on this board think they work on weekends and Holidays... 🤣
And it took a week to even get that lame response.
LOL that was for one question, Imaging trying to get a cancer therapy approved?????
Danish Dude, This is an amazing post of information.
I think they need more young blood than a new 78yo board member…
I want to see a clear capital markets strategy.
Do you realize they don’t have an external adviser (banker) to guide them on a possible transaction or to introduce them to institutional investors?
It’s mind boggling.
You’re an investment banker/adviser you know how it works.
If envy was not a sin, I would envy you.
Congrats on loading at such low price.
I was one of the lucky ones who was able to buy a mountain of shares at 14 and 15 cents in 2017.
GLTU
LP daring BP to call her "bluff"?
ILT,
Really appreciate your reply.
Every long was excited seeing Kristyn Power liked Matthew Vandermast's post.
https://www.linkedin.com/feed/update/urn:li:activity:7173690886331990018/
They should be more excited to see the director of technology transfer from Takeda liked Vikas Moolchandani's post. That's also one of the reasons that I said there would be no BO.
But during the past ten years, there was a certain time interval the sp was less than 20 cents. The first poly-iclc trial results were published in 2011. The second one had the abstract published in 2015 if I am not mistaken. From science perspective, those results indicated back then that DCVax-L is amazing. Especially for the second one, the presentation over ten years ago already showed that with only six patients (the objective is 20 patients) enrolled in the poly-iclc group the conclusion can be drawn already. I believe all the longs were attracted to this company purely by science, were they not? That's why I thought a lot of longs would load a lot when sp was around teens. Did I hurt someone long's feeling? If I did, my apologies.
Take everything I posted with the biggest grain of salt.
Followers
|
1625
|
Posters
|
|
Posts (Today)
|
39
|
Posts (Total)
|
695382
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |